Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

1.860 -0.140 (-7.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Via ACCESS Newswire
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Via ACCESS Newswire
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Via ACCESS Newswire
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Via ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Via ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Via ACCESSWIRE
Ensysce Biosciences Regains Full Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Via ACCESSWIRE
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Via ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
Via ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Via ACCESSWIRE
Ensysce Biosciences Receives Notice from Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Via ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
Via ACCESSWIRE
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Via ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Via ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
Via ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Via ACCESSWIRE
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Via ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.